Indian generics giant Dr Reddy’s Laboratories announced on 13 July 2015 the launch of generic memantine hydrochloride tablets in dosages of 5 and 10 mg, following approval of the company’s abbreviated new drug application (ANDA) by the US Food and Drug Administration (FDA).
Alzheimer generic launched in the US
Generics/News
|
Posted 28/08/2015
0
Post your comment
The drug is a generic version of Forest Laboratories blockbuster Alzheimer’s disease treatment Namenda (memantine). Namenda had US sales of approximately US$1.4 billion for the twelve months ending May 2015, according to IMS Health.
Actavis, and its subsidiary Forest Laboratories, have already been surrounded by controversy after the companies were forced to continue selling the immediate-release version of Namenda by New York’s attorney general Eric Schneiderman [1]. The companies had planned to discontinue the immediate-release version of the Alzheimer’s drug (Namenda IR) and switch patients to an extended-release version (Namenda XR). The US patent on Namenda IR expired in January 2015, while the patent on the newer version expires in 2025.
Forest Laboratories has also filed a lawsuit against generics makers Sun Pharma Global, Teva Pharmaceuticals USA and Wockhardt Bio, all of whom have filed ANDAs with FDA seeking approval to market generics of Namenda XR [2].
Related article
Generics applications under review by EMA – 2013 Q4
References
1. GaBI Online - Generics and Biosimilars Initiative. Actavis agrees to continue making Alzheimer’s drug for now [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2015 Aug 28]. Available from: www.gabionline.net/Generics/News/Actavis-agrees-to-continue-making-Alzheimer-s-drug-for-now
2. GaBI Online - Generics and Biosimilars Initiative. Forest Labs files lawsuit to stop generic memantine [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2015 Aug 28]. Available from: www.gabionline.net/Generics/News/Forest-Labs-files-lawsuit-to-stop-generic-memantine
Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.
Copyright – Unless otherwise stated all contents of this website are © 2015 Pro Pharma Communications International. All Rights Reserved.
Source: Dr Reddy’s
Research
Japan’s drug shortage crisis: challenges and policy solutions
Saudi FDA drug approvals and GMP inspections: trend analysis
Related content
Most viewed articles
The best selling biotechnology drugs of 2008: the next biosimilars targets
Post your comment